Clinical trial
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative…
NCT00307827 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00307827 |
|---|---|
| Title | Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC) |
| Official title | A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 38 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Mar 28, 2006 |
| Last update posted | Apr 27, 2012 |
| Countries | Canada, Croatia, Italy, Russia, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: